RxLedger

Zenpep (Lipase/Protease/Amylase) — Medicare Part D spending

Multiple manufacturers (2) · Rank #123 by total Part D spend · CMS data year 2023

Medicare Part D spent $443,196,731 on Zenpep (Lipase/Protease/Amylase) in 2023, the #123 drug by total Part D spending out of 3,598 drugs. That worked out to about $11.22 per dosage unit, $2,331 per claim and $9,568 per beneficiary, across 190,147 claims for 46,322 beneficiaries. Average spending per dosage unit rose +10.2% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

Zenpep (Lipase/Protease/Amylase) spending at a glance (2023)

MetricZenpep (Lipase/Protease/Amylase)
Total Part D spending (2023)$443,196,731
Total spending (2022)$340,874,500
Year-over-year change in total spending+30.0%
Average spending per dosage unit (2023)$11.22
Change in spend per dosage unit (YoY)+10.2%
Avg annual change per dosage unit (2019-2023 CAGR)+10.8%
Average spending per claim (2023)$2,331
Average spending per beneficiary (2023)$9,568
Total claims (2023)190,147
Beneficiaries (2023)46,322
Total dosage units (2023)39,622,745
Manufacturer(s)Multiple manufacturers (2)
National rank by total spend (of 3,598 drugs)#123

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

2022 vs 2023

Zenpep (Lipase/Protease/Amylase): year-over-year Medicare Part D figures. Per-claim/per-beneficiary "change" omitted because it mixes price and utilization. Source: CMS Medicare Part D Spending by Drug (data year 2023).
Metric20222023Change
Total spending$340,874,500$443,196,731+30.0%
Avg spend per dosage unit$10.18$11.22+10.2%
Avg spend per claim$2,036$2,331
Avg spend per beneficiary$8,701$9,568
Total claims167,458190,147
Beneficiaries39,17846,322

How Zenpep compares with nearby drugs

Drugs with total Part D spending closest to Zenpep (Lipase/Protease/Amylase):

Zenpep (Lipase/Protease/Amylase) and its nearest-spend peers. Source: CMS Medicare Part D Spending by Drug (data year 2023), data year 2023.
Drug (rank)Total spend 2023Per dosage unitPer-unit YoY
Zenpep (Lipase/Protease/Amylase) (this drug, #123)$443,196,731$11.22+10.2%
Orencia Clickject (Abatacept) (#121)$451,311,111$1,402.17+6.6%
Humira(Cf) (Adalimumab) (#122)$445,800,874$3,609.32+9.1%
Tyvaso Dpi (Treprostinil) (#124)$436,921,533$195.61+7.5%
Dovato (Dolutegravir Sodium/Lamivudine) (#125)$433,449,386$98.89+5.6%
Stiolto Respimat (Tiotropium Br/Olodaterol HCl) (#126)$432,253,137$118.33+3.5%

Frequently asked questions

How much does Medicare Part D spend on Zenpep?

Medicare Part D spent $443,196,731 on Zenpep (Lipase/Protease/Amylase) in 2023 (the latest CMS data year), across 190,147 claims for 46,322 beneficiaries. That ranks #123 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.

What is the average spending per dosage unit for Zenpep?

In 2023, the weighted average Medicare Part D spending per dosage unit for Zenpep (Lipase/Protease/Amylase) was $11.22. Compared with 2022 it rose +10.2%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.

Who makes Zenpep?

CMS attributes Zenpep (Lipase/Protease/Amylase) to Multiple manufacturers (2) in the 2023 Part D spending file. Average spending per claim was $2,331 and per beneficiary $9,568.

Is the Zenpep figure the price I pay?

No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.

Keep exploring

Source & what this means

Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.

Last updated: 2026-06-20